Business Updates

Vivos Inc. Provides October Business Update

Kennewick, WA — November 2, 2026 — Vivos Inc. (OTCQB: RDGL) (“Vivos” or the “Company”) is pleased to update shareholders on October progress across RadioGel® human therapy, IsoPet® veterinary therapy, and the PrecisionGel™ polymer platform.

October 2026 Highlights
Earlier in September we conducted our Business Strategy meeting, in which we reached consensus on the actions required to complete our current development phase and to launch Vivos into the final major business phase. The following summarizes the progress on those actions this month.

Board of Directors Transformation
We are increasing the membership on the Board of Directors to align with the Major Business Phase strategy. Potential new directors have been identified and interviewed, each providing expertise directly aligned with the next phase of execution.

Their draft contracts were delayed since our Omnibus Security and Incentive Plan recently expired and needs to be extended. The fastest way to gain proxy vote approval for this extension was to issue new Preferred D shares, with enhanced voting authority. Our chairman purchased these shares at a price of $0.08 to demonstrate his support of the company. We hope to gain approval at the upcoming shareholder meeting, and then to activate the contracts of the new Board members by the end of this year.

APEL Production Center Optimization
We have completed construction of a state-of-the-art clean room at our APEL facility. This supports continued production and shipping of IsoPet® while positioning us to begin production of RadioGel®. We are also ordering equipment for our international contract manufacturer in India to start our second production center by early 2027. Operating two production centers will expand our geographic reach to strategic target countries and provide redundancy that eliminates single-point-of-failure risk.

IsoPet® Animal Therapy
Our September strategic meeting concluded that the fastest path to generating a profitable business is through animal therapy. We have been actively implementing these recommendations focusing on the strategic target countries.

  • Canada
    As the first step to expedite treating animals and humans in that country, we have prepared our application to submit to the Therapeutic Products Directorate in Canada, to pursue device classification.
  • Mexico
    We are in the early stages of partnering with a major hospital. To support these efforts, we have signed a contract with a consultant who has relevant experience in Mexico. The consultant will assist with market entry, regulatory considerations, and local relationships. We completed an initial trip earlier this year and will conduct a second trip before year-end to advance discussions and evaluate next steps.
  • United Kingdom
    We have signed a contract with Andy Ferrie, a consultant with more than 35 years of experience in the radiopharmaceutical and radionuclide therapy space. He brings extensive industry relationships and key contacts that will support our activities in the UK. The United Kingdom is recognized for producing some of the most highly regarded clinical data in the world, making it an attractive market for further development and potential expansion of IsoPet® and RadioGel®.
  • Australia, UAE, Saudi Arabia
    We are in the early stages of exploring opportunities in Australia, the United Arab Emirates, Saudi Arabia, and Turkey. Following a series of video conference meetings and face-to-face discussions at the October European Nuclear Conference, we signed Non-Disclosure Agreements with parties in Australia, the UAE, and Saudi Arabia. Discussions are also progressing in Turkey, and we signed a Memorandum of Understanding with a potential IsoPet® distribution partner focused on equine and camel clinics.

This month we successfully shipped a record volume of IsoPet® in a single production week to six separate clinics. We are currently implementing cost-reduction initiatives that include reducing state licensing fees and facility lease costs, as well as accelerating the daily production rate. Our objective is to lower the cost per therapy to support progress toward breakeven and eventual profitability for animal therapies. These efforts will be paired with the removal of discounts to our list price for IsoPet®, which will improve realized revenue. In the longer term, we are exploring production automation options.

Production costs per run decrease as the volume of IsoPet® treatments increases. Marketing in this sector is sophisticated, but our enhanced website has proven successful, and we maintain booths at key conferences. Publishing data from successful therapies is vital to convincing veterinarians and oncologists at animal clinics. Dr. Rebecca Krimins has submitted a paper on our VX2 tumor study. This month, Dr. Kevin Drygas of Capital Veterinary Specialists presented on post-resection margin treatments at the American College of Veterinary Surgeons(ACVS) Surgery Summit. The presentation was very well received and generated follow-up interest from several well-known veterinary clinics. We are in the final stages of peer review for a single-case study, which we expect to be published in November. Treating the margins of resected tumors is a high-growth area in animal therapy and represents a promising potential opportunity in human medicine, subject to regulatory review and approval.

Human Therapy Clinical Studies
Domestically, in July the FDA authorized the first-in-human therapy (under an IDE) at a leading U.S. academic medical center. Since then, we have been engaged in the process of obtaining approval from their Institutional Review Board. This month we were endorsed by their internal pre-IRB submittal committees and received approval of the requested documents we provided. As a result, the IRB has now begun the final review process. Once approved, we anticipate study enrollment and initiation by mid-2027, but possibly sooner. We are also focusing on preparing for a potential FDA audit of our production facility and scheduling refresher training sessions for our principal investigator.

About Vivos Inc.
Vivos Inc. is advancing Precision Radionuclide Therapy™ (PRnT) platforms designed to deliver targeted cancer treatment to tumors and surgical margins while limiting exposure to surrounding healthy tissue. Through RadioGel®, IsoPet®, and its proprietary polymer technologies, Vivos is developing applications in human and veterinary oncology. RadioGel® is investigational and is not approved for commercial human use in the United States.

Forward Looking Statements
This business update contains forward-looking statements regarding future development, regulatory activities, commercialization opportunities, and potential applications of Vivos’ technologies. Actual results may differ materially from those projected due to risks and uncertainties. Vivos undertakes no obligation to update forward-looking statements except as required by law.

Contact: Vivos Inc. Investor Relations | investors@vivosinc.com

About the Author:

Previous Post
Vivos Inc. Business Update: Progress on the Mayo Clinic Clinical Trial for RadioGel
keyboard_arrow_up